ArticleTranslational oncology2026
Combination of APS, HMGN1, and anti-TNFR2 antibody remodels the tumor immune microenvironment to enhance antitumor immunity in colorectal cancer.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Astragalus polysaccharide (APS), a major bioactive component of Astragalus membranaceus, has shown antitumor potential through modulation of the tumor microenvironment (TME) and immune responses. High mobility group nucleosome binding domain 1 (HMGN1), a natural agonist of TLR4, promotes dendritic cell (DC) maturation, whereas an anti-TNFR2 antibody relieves immunosuppression by targeting regulatory T cells (Tregs). Although immunotherapy holds promise for the treatment of colorectal cancer (CRC), more effective combination strategies are still needed. Here, we investigated the therapeutic efficacy of APS in combination with HMGN1 and an anti-TNFR2 antibody in a murine CRC model. This triple combination regimen eradicated CT26 tumors and induced durable, tumor specific immune memory. Mechanistic analyses showed that the treatment activated DCs in vitro and induced profound remodeling of the TME in vivo, including increased CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.